Tirzepatide Side Effects: FDA-Labelled Risks Explained
Tirzepatide is the dual GIP/GLP-1 receptor agonist sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). The most common side effects are gastrointestinal, nausea, diarrhoea, decreased appetite, vomiting, constipation. The most serious are pancreatitis, gallbladder disease, acute kidney injury, severe hypoglycaemia with insulin or sulfonylureas, and a boxed warning about thyroid C-cell tumours.
Tirzepatide (Mounjaro, Zepbound) (Tirzepatide) is approved as a Dual GIP/GLP-1 receptor agonist. Most common side effects are gastrointestinal (nausea, vomiting, diarrhoea, constipation). Serious risks include pancreatitis, kidney injury, gallbladder disease and hypoglycaemia with insulin. It carries an FDA boxed warning for thyroid C-cell tumours.
Key Takeaways
- Tirzepatide carries a boxed warning for thyroid C-cell tumours, contraindicated if personal or family history of medullary thyroid carcinoma or MEN2.
- Most common side effects: nausea, diarrhoea, decreased appetite, vomiting, constipation, abdominal pain.
- Major label warnings: pancreatitis, acute kidney injury, gallbladder disease, hypoglycaemia with insulin/sulfonylureas, hypersensitivity reactions, diabetic retinopathy worsening.
- At Zepbound doses, tirzepatide can reduce oral contraceptive effectiveness, use a non-oral or barrier method for 4 weeks after dose changes.
- Disclose tirzepatide use to your anaesthetist before any procedure, delayed gastric emptying creates aspiration risk.
- Check tirzepatide against your full medication list with the Allmeds drug interaction checker.
What is Tirzepatide, and what is it used for?
Tirzepatide is a once-weekly injectable dual GIP/GLP-1 agonist sold as Mounjaro for type 2 diabetes and Zepbound for weight management.
| Property | Detail |
|---|---|
| Drug name | Tirzepatide |
| Brand names | Mounjaro (T2D), Zepbound (weight management) |
| Drug class | Dual GIP / GLP-1 receptor agonist |
| FDA approval status | Approved, type 2 diabetes (Mounjaro), chronic weight management (Zepbound) |
| Route | Subcutaneous injection, once weekly |
| Boxed warning | Thyroid C-cell tumours (animal data) |
| Common GI side effects | Nausea, diarrhoea, vomiting, decreased appetite, constipation, abdominal pain |
| Major label warnings | Pancreatitis, kidney injury, gallbladder disease, hypoglycaemia, retinopathy, contraceptive efficacy |
What are the side effects of Tirzepatide?
The FDA prescribing information for Tirzepatide groups side effects into common gastrointestinal symptoms (very frequent at initiation and dose escalation) and serious warnings (less frequent but clinically important). The table below summarises the labelled categories with severity colour-coding.
| Side Effect Category | What May Occur | Why It Matters |
|---|---|---|
| Pancreatitis | Severe, persistent abdominal pain (sometimes radiating to the back), nausea, vomiting | All GLP-1 labels warn about acute pancreatitis. Stop the medicine and seek urgent assessment. |
| Thyroid C-cell tumours (boxed warning) | Neck mass, hoarseness, difficulty swallowing, persistent neck pain | Animal studies show medullary thyroid carcinoma risk. Contraindicated if personal or family history of MTC or MEN2. |
| Acute kidney injury | Reduced urine output, swelling, fatigue, usually after vomiting or diarrhoea | Dehydration from GI side effects can precipitate AKI, particularly in patients with prior renal disease. |
| Severe hypoglycaemia | Sweating, shakiness, confusion, palpitations, seizure, loss of consciousness | Risk rises sharply when combined with insulin or sulfonylureas. Dose reduction of the other glucose-lowering drug is usually required. |
| Gallbladder disease | Right-upper abdominal pain, fever, jaundice | Cholelithiasis and cholecystitis are reported, especially with rapid weight loss. |
| Severe gastrointestinal reactions | Persistent nausea, vomiting, diarrhoea, constipation, abdominal pain | Common and dose-dependent. Most pronounced during initiation and dose escalation. |
| Diabetic retinopathy worsening | Blurred vision, vision changes | Rapid glucose lowering has been associated with transient worsening, relevant in long-standing type 2 diabetes. |
| Hypersensitivity reactions | Rash, urticaria, angioedema, anaphylaxis | Stop the medicine and seek urgent care for serious allergic features. |
| Injection-site reactions | Redness, swelling, itching, induration at the injection site | Usually mild; persistent reactions warrant clinical review. |
| Aspiration risk during anaesthesia | Delayed gastric emptying may leave food in the stomach during sedation | Disclose GLP-1 use to your anaesthetist before any procedure or surgery. |
Taking Tirzepatide alongside other medications?
Check Tirzepatide against your full medication list instantly. Allmeds scans the widest drug interaction database in minutes.
How does Tirzepatide work, and why does that drive the side effects?
Tirzepatide is the first approved dual GIP/GLP-1 receptor agonist. By activating both receptors it produces greater weight loss and glucose lowering than GLP-1-only agonists in head-to-head trials. The side-effect profile is dominated by slowed gastric emptying (nausea, reflux, anaesthetic aspiration risk) and glucose-dependent insulin release (hypoglycaemia with insulin/sulfonylureas).
Can you drink alcohol while taking Tirzepatide?
Alcohol is not contraindicated but can worsen nausea, dehydration, and hypoglycaemia in those on insulin or sulfonylureas.
Symptoms and when to seek care
Seek urgent medical assessment if you experience any of the following while taking Tirzepatide:
- Severe, persistent abdominal pain (possible pancreatitis)
- Sudden swelling of the face, lips, tongue or throat, or difficulty breathing (allergic reaction)
- Right-upper abdominal pain with fever or jaundice (gallbladder disease)
- Severe vomiting or diarrhoea with reduced urine output (dehydration / kidney injury)
- Severe hypoglycaemia, sweating, confusion, palpitations, loss of consciousness (especially if also on insulin or sulfonylurea)
- New neck mass, hoarseness, or difficulty swallowing (thyroid concern)
- New or worsening depression, mood changes, or suicidal thoughts (Wegovy/Zepbound)
Common Questions About Tirzepatide Side Effects
Nausea, diarrhoea, decreased appetite, vomiting, constipation, and abdominal pain. Most are worst during dose escalation and improve over weeks.
Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates only GLP-1. In head-to-head trials (SURPASS-2), tirzepatide produced greater HbA1c reduction and weight loss than semaglutide. Both carry the same boxed warning and similar serious risks.
Thyroid C-cell tumours, based on rodent studies. Tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
Yes, usually secondary to dehydration from vomiting or diarrhoea. Maintain hydration during initiation and dose escalation, and discuss any pre-existing kidney disease with your prescriber.
Yes. Tirzepatide slows gastric emptying. Disclose use before any procedure involving sedation or general anaesthesia.
References
- U.S. Food & Drug Administration. Ozempic (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Wegovy (semaglutide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Mounjaro (tirzepatide) prescribing information. fda.gov.
- U.S. Food & Drug Administration. Zepbound (tirzepatide) prescribing information. fda.gov.
- European Medicines Agency. Ozempic, Wegovy, Mounjaro, EPAR product information. ema.europa.eu.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
Check Tirzepatide against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.